Veracyte (VCYT) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
10 Jun, 2026Opening remarks and agenda
Chair welcomed attendees, introduced board members, executive team, auditors, and legal counsel.
Meeting was called to order and the agenda was outlined, including director elections, auditor ratification, executive compensation, and equity plan amendment.
Corporate governance
Notice of meeting and voting rights were confirmed for stockholders of record as of April 15, 2026.
Quorum was established with 91% of shares represented, allowing business to proceed.
Inspector of Election and voting procedures were detailed, ensuring transparency and compliance.
Overview of voting outcomes
All nine nominated directors were elected for a one-year term expiring at the 2027 annual meeting.
Appointment of Ernst & Young LLP as independent auditor for 2026 was ratified.
Executive compensation was approved on a non-binding advisory basis.
Amendment to the 2023 Equity Incentive Plan, increasing authorized shares by 3.5 million, was approved.
Latest events from Veracyte
- Q3 2024 revenue up 29% to $115.9M, net income $15.2M, guidance raised on strong test growth.VCYT
Q3 20248 Jul 2026 - Strong growth in core assays, strategic SAS exit, and new product launches drive future expansion.VCYT
Leerink Global Healthcare Conference 20258 Jul 2026 - Double-digit growth, early profitability, and global expansion with major launches planned.VCYT
44th Annual J.P. Morgan Healthcare Conference8 Jul 2026 - Double-digit growth continues as new products and strong evidence fuel expansion.VCYT
Wolfe Research Healthcare Conference 20258 Jul 2026 - Raised 2024 guidance after strong Q1, driven by core test growth and new product pipeline.VCYT
The 44th Annual William Blair Growth Stock Conference8 Jul 2026 - Q2 2024 revenue up 27–28% to $114.4M, net income $5.7M, and guidance raised for 2024.VCYT
Q2 20248 Jul 2026 - Q1 2025 revenue up 18% to $114.5M, net income $7M, EBITDA margin 21.6%, Marseille unit in bankruptcy.VCYT
Q1 20258 Jul 2026 - Record 2024 revenue and profit, with double-digit growth and margin expansion expected in 2025.VCYT
Q4 20241 Jul 2026 - Double-digit growth, new launches, and strong margins drive an optimistic outlook.VCYT
Jefferies Global Healthcare Conference 20264 Jun 2026